Abrégé

Provided is a simple and environmentally friendly process for preparing tertiary amines by the aminomethylation of alkenes. This process features relatively mild reaction conditions and no metal catalyst.

Classes IPC  ?

• C07C 209/78 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p. ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné à partir de composés carbonylés, p. ex. à partir de formaldéhyde, et d'amines ayant des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons, avec formation de méthylène-diarylamines
• C07C 209/60 - Préparation de composés contenant des groupes amino liés à un squelette carboné par des réactions de condensation ou d'addition, p. ex. réaction de Mannich, addition d'ammoniac ou d'amines à des alcènes ou à des alcynes ou addition de composés, contenant un atome d'hydrogène actif, à des bases de Schiff, à des quinone-imines ou à des aziranes

Abrégé

A reduction ratio changing device, so-called DCRR, for a mechanical chain transmission system includes a toothing. The toothing of the DCRR includes a portion, so-called the helical portion, forming a toothed helix winding around an axis of revolution of the DCRR and a portion, so-called the circular portion, forming a toothed planar circle whose centre coincides with the axis of revolution of the DCRR. The helical portion of the toothing extends from a distal end of the toothing of the DCRR towards the circular portion of the toothing. The circular portion of the toothing of the DCRR forms a proximal end of the toothing of the DCRR.

Classes IPC  ?

• B62M 9/08 - Transmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire de rapport variable utilisant une seule chaîne, courroie ou organe similaire comportant une roue, motrice ou entraînée, montée excentriquement ou de forme elliptiqueTransmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire de rapport variable utilisant une seule chaîne, courroie ou organe similaire avec une roue motrice ou entraînée expansible
• B62M 9/00 - Transmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire
• F16H 55/12 - Organes dentésVis sans fin le corps ou la jante étant constitués d'éléments amovibles
• F16H 55/30 - Roues à chaînes

Abrégé

An installation intended to separate the components of a mixture containing fibers (2) and granules (3) is provided. The installation comprises a tribocharger (4) for conferring an electrostatic charge upon the components (2, 3), and at least one pair of electrodes (5, 6) for generating a separating electric field that conveys the charged components, according to their polarity, up to collectors (10, 11). The tribocharger (4) has a containment grating (14) arranged so as to retain the components in the tribocharger (4) until the components (2, 3) have reached a sufficient charge, then to allow the components, once charged, through into the gap (7), from which point the components (2, 3) reach their collector (10, 11) under the effect of the separating electric field.

Classes IPC  ?

• B03C 7/00 - Séparation par effet électrostatique des solides mélangés
• B03C 7/06 - Séparateurs ayant des supports pour le matériau traité, de forme cylindrique
• B03C 7/10 - Séparateurs dans lesquels le matériau tombe en cascades

Abrégé

A separation method making it possible, from a mixture containing fibers and granules, to separate the fibers from the granules is provided. The method comprises a supply step during which the mixture is brought into a receptacle provided with a screen, a dissociation step which involves carrying out, simultaneously, an agitation sub-step in which mechanical mixing of the mixture contained in the receptacle is performed and a neutralization sub-step in which the mixture being mixed in the receptacle is exposed to bipolar charges in order to neutralize electrostatic charges of the fibers and the granules, followed by a screening step during which the mixture treated in accordance with the dissociation step is passed over the screen in order to retain in the receptacle a first product enriched in fibers while a second product enriched in granules is discharged through the screen.

Classes IPC  ?

• B07B 1/22 - Tambours tournants
• B07B 4/06 - Séparation des solides, obtenue en soumettant leur mélange à des courants de gaz pendant que le mélange tombe en utilisant des tambours en rotation
• B07B 4/08 - Séparation des solides, obtenue en soumettant leur mélange à des courants de gaz pendant que le mélange est supporté par des cribles, des tamis ou des éléments mécaniques analogues

Abrégé

The present invention relates to compounds of formula (I), wherein: The present invention relates to compounds of formula (I), wherein: wherein: A is an anti-cancer agent, Y is an electron-withdrawing or electron-donating group, L represents a linker -A1-A2-A3-A4-A5-A6- A1, A3 and A5 representing a (C1-C6) alkylene radical, A2 representing a group obtained by click chemistry, A4 being a (C1-C32) alkylene radical interrupted by at least one oxygen atom, A6 being a radical selected from the group consisting of: —NRc—, —O— and —S—, Rc representing H or a (C1-C12) alkyl group, and L′ is a radical capable of reacting with an amino, hydroxy or thiol function.

Classes IPC  ?

• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 35/00 - Agents anticancéreux

Abrégé

An optical element includes a transparent substrate and an intermediate coating extending over at least one main surface of the substrate. The intermediate coating has a plurality of dense thin layers which alternate in having a first index refractive index and a second refractive index, the first refractive index being greater than the second refractive index. An optical element includes a transparent substrate and an intermediate coating extending over at least one main surface of the substrate. The intermediate coating has a plurality of dense thin layers which alternate in having a first index refractive index and a second refractive index, the first refractive index being greater than the second refractive index. The optical element further includes at least one porous layer extending over the intermediate coating, opposite the substrate. The porous layer has a third refractive index that is lower than the first and second refractive indices.

Classes IPC  ?

• G02B 1/11 - Revêtements antiréfléchissants
• B64D 47/00 - Équipements non prévus ailleurs

Abrégé

The present invention relates to a composition comprising: —either at least ethyl-β-D-glucuronide, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-β-D-glucuronide probe) and at least ethyl-β-D-galactopyranoside (or ethyl-β-D-galactopyranoside probe), the ethyl part of which comprises at least one non-radioactive isotope; —or at least ethyl-α-mannopyranoside, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-β-D-glucuronide probe); for use thereof as a diagnostic and/or prognostic agent.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a nickel-based superalloy comprising in weight percentages: 5.0 to 6.0% of aluminium, 6.0 to 9.0% of tantalum, 1.0 to 5.0% of cobalt, 5.0 to 7.5% of chromium, 0 to 1.0% of molybdenum, 4.0 to 6.0% of tungsten, 0.50 to 3.5% of rhenium, 1.0 to 4.0% of platinum, 0.05 to 0.25% of hafnium, 0 to 0.15% of silicon, the remainder consisting of nickel and unavoidable impurities. The invention also relates to a single-crystal blade comprising such an alloy and to a turbomachine comprising such a blade.

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• C22C 19/00 - Alliages à base de nickel ou de cobalt, seuls ou ensemble
• C22C 30/00 - Alliages contenant moins de 50% en poids de chaque constituant
• F01D 5/28 - Emploi de matériaux spécifiésMesures contre l'érosion ou la corrosion

Abrégé

The invention relates to a characterisation method which comprises the following steps: - taking an autoradiograph of the solid sample, including recording the following data for each detected α or β particle: time of detection of the particle, spatial coordinates of an emergence point of the particle, charge deposited by the particle upon detection; - analysing the recorded data so as to detect two successive isotopes in the disintegration chain, with the following sub-steps: * locating pairs of particles verifying the following criteria: detection times separated by a time interval less than a given limit; distance between the respective emergence points less than a given limit; charge deposited by the detected first particle corresponding to the disintegration of the first isotope; charge deposited by the detected second particle corresponding to the disintegration of the second isotope; and * counting the number of pairs identified.

Classes IPC  ?

• G01T 1/178 - Dispositions de circuits non adaptés à un type particulier de détecteur pour la mesure d'une activité spécifique en présence d'autres substances radioactives, p. ex. des substances naturelles, présentes dans l'air ou dans des liquides tels que l'eau de pluie
• G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations

Abrégé

A method for helping to bend a rod that can be implanted in a patient, the method including the following steps: acquiring one or more measurements of distance and/or angle between elements of a vertebral column of the patient; determining a type of vertebral column of the patient, on the basis of the measurements, according to a classification; identifying one or more invariant parameters corresponding to the determined type of vertebral column; calculating one or more radii of curvature for bending a rod on the basis of the previously identified invariant parameters and the determined type of vertebral column; obtaining a representation of the rod bent according to the one or more radii of curvature; and displaying the representation.

Classes IPC  ?

• A61B 17/88 - Moyens ou procédés pour implanter ou pour extraire des dispositifs de fixation interne
• A61B 17/56 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet
• A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales

Abrégé

The present invention relates to the field of genomics. The invention relates more particularly to new microsatellite markers and their uses, in particular for determining the microsatellite status of a tumor, in particular of a tumor from a human subject. The description provides methods for analyzing DNA microsatellite loci. It also relates to the tools, kits and systems that can be used to implement such an analysis.

Classes IPC  ?

• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.

Classes IPC  ?

• C07D 209/08 - IndolesIndoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
• C07C 311/00 - Amides d'acides sulfoniques, c.-à-d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
• C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
• C07D 211/38 - Atomes d'halogènes ou radicaux nitro
• C07D 215/06 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle comportant uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
• C07D 279/02 - Thiazines-1, 2Thiazines-1, 2 hydrogénées
• C07D 295/185 - Radicaux dérivés d'acides carboxyliques d'acides carboxyliques aliphatiques
• C07D 519/04 - Alcaloïdes de dimères d'indole, p. ex. vincaleucoblastine
• C07D 213/12 - Préparation par cyclisation utilisant de l'ammoniac, des amines, des sels d'amines ou des nitriles à partir de composés non saturés
• C07C 209/74 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p. ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné par halogénation, halogénhydratation, déshalogénation ou déshalogénhydratation
• C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide

Abrégé

A sleep analyzer, method and system with reduced invasiveness and limited human intervention to monitor sleep in an intensive healthcare unit.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/291 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
• A61B 5/372 - Analyse des électroencéphalogrammes

Abrégé

The invention relates to a nickel-based superalloy comprising, in weight percentages, 5.0 to 6.0% aluminium, 6.5 to 8.5% tantalum, 0 to 1.0% titanium, 1.0 to 4.0% cobalt, 5.0 to 8.0% chromium, 0 to 0.5% molybdenum, 3.0 to 4.0% tungsten, 3.75 to 5.75% rhenium, 3.5 to 5.0% platinum, 0.05 to 0.25% hafnium and 0 to 0.15% silicon, the remainder being made up of nickel and inevitable impurities. The invention also relates to a single-crystal blade (20A, 20B) comprising such an alloy and to a turbine engine (10) comprising such a blade (20A, 20B).

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• F01D 5/28 - Emploi de matériaux spécifiésMesures contre l'érosion ou la corrosion

Abrégé

The inventors aim to assess IL-33 and HMGB1 contributions as alarmins to I/R injury following solid organ transplantation in particular liver transplantation. This study was conducted from a prospective biological collection and a clinical database of 40 liver transplant recipients in Tours hospital center. Serum IL-33 and HMGB1 levels were determined at graft reperfusion, at the end of the liver transplantation and at postoperative day 1 and 3. A post-reperfusion liver biopsy was systematic. Serum IL-33 increase is associated with: i) severe-moderate liver lesions; ii) an early allograft dysfunction; iii) a post-reperfusion syndrome occurrence; iv) a post liver transplantation acute kidney injury occurrence. Serum HMGB1 increase is associated with: i) an early allograft dysfunction; ii) a post-reperfusion syndrome occurrence. IL-33 and HMGB1 thus contribute as alarmins to I/R injury in human liver transplantation. Their serum levels are predictive of I/R injury severity and its clinical impact. Serum assay for IL-33 and HMGB1 upon graft reperfusion could be used as early biomarkers of early allograft function in solid organ transplantation, in particular in liver transplantation.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A device for measuring at least one flow parameter of a fluid through a duct, in particular the flow rate thereof, including a portion forming an obstacle, intended to be brought into contact with the flow, the shape of which being chosen so as to generate turbulence in the flow; a vibration sensor sensitive to vibrations caused on the portion forming an obstacle by the turbulence; a processing unit configured to calculate the flow parameter of the fluid based on at least one vibration signal delivered by the vibration sensor.

Classes IPC  ?

• G01F 1/325 - Moyens de détection de quantités utilisées comme variables de substitution corrélées à l’effet des tourbillons
• G01F 1/32 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en utilisant des effets mécaniques par détection des effets dynamiques de l’écoulement utilisant des débitmètres à tourbillons

Abrégé

The present invention relates to a method for producing bis(fluorosulfonyl)imide acid, which is economically feasible at industrial scale and which provides a high-purity product.

Classes IPC  ?

• C01B 21/086 - Composés contenant de l'azote et des non-métaux contenant un ou plusieurs atomes de soufre
• C07C 311/00 - Amides d'acides sulfoniques, c.-à-d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
• H01M 10/0568 - Matériaux liquides caracterisés par les solutés

Abrégé

The present invention relates to a separating apparatus (100) intended to separate two families of components (2, 3) of a mixture (1) placed in a receptacle (5) provided with a screen (6), said apparatus comprising a first electrode (7), a second electrode (8), and a generator (10) which generates, between said first electrode and second electrode (7, 8), an alternating electric agitation field (11), capable of alternately projecting all or some of the components (2, 3) of the mixture (1) contained in the receptacle (5) towards or against the first electrode (7) and then towards or against the second electrode (8), in order to generate mechanical shocks on said components (2, 3) which help to break up the mixture (1) within the receptacle (5) and facilitate the passage of components (3) belonging to the second family through the screen (6), while said screen (6) ensures that components (2) belonging to the first family are retained in the receptacle (5).

Classes IPC  ?

• B03C 7/02 - Séparateurs
• B03C 7/06 - Séparateurs ayant des supports pour le matériau traité, de forme cylindrique
• B03C 7/00 - Séparation par effet électrostatique des solides mélangés

Abrégé

The present invention relates to a composition comprising an aqueous phase, a polyene antifungal and lipid nanoparticles which are dispersed in the aqueous phase, said lipid nanoparticles comprising an oily internal phase and an envelope, the envelope comprising a polyglycol ester of a hydroxy fatty acid, the polyene antifungal being dispersed in the aqueous phase and/or being part of the lipid nanoparticles. It further relates to lipid nanoparticles comprising an antifungal polyene, an oily internal phase and an envelope, the envelope comprising a polyglycol ester of a hydroxy fatty acid and the polyene antifungal being part of the lipid nanoparticles, and preparation method thereof. It also relates to the composition or lipid nanoparticles of the invention for use in the prevention or treatment of an infection caused by a fungus, preferably a fungus of the Mucorales order.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61P 33/00 - Agents antiparasitaires

Abrégé

Provided is a simple and environmentally friendly process for preparing tertiary amines by the aminomethylation of alkenes. This process features relatively mild reaction conditions and no metal catalyst.

Classes IPC  ?

• C07C 209/60 - Préparation de composés contenant des groupes amino liés à un squelette carboné par des réactions de condensation ou d'addition, p. ex. réaction de Mannich, addition d'ammoniac ou d'amines à des alcènes ou à des alcynes ou addition de composés, contenant un atome d'hydrogène actif, à des bases de Schiff, à des quinone-imines ou à des aziranes
• C07C 209/28 - Préparation de composés contenant des groupes amino liés à un squelette carboné par alkylation réductive, avec des composés carbonylés, d'ammoniac, d'amines ou de composés ayant des groupes réductibles en groupes amino par réduction avec d'autres agents réducteurs
• C07C 211/02 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé acyclique

Abrégé

The present invention relates to a simple and environmentally friendly process for preparing secondary amines by the aminomethylation of alkenes. This process features relatively mild reaction conditions, i.e. at a temperature lower than 115 °C.

Classes IPC  ?

• C07C 209/60 - Préparation de composés contenant des groupes amino liés à un squelette carboné par des réactions de condensation ou d'addition, p. ex. réaction de Mannich, addition d'ammoniac ou d'amines à des alcènes ou à des alcynes ou addition de composés, contenant un atome d'hydrogène actif, à des bases de Schiff, à des quinone-imines ou à des aziranes
• C07C 209/00 - Préparation de composés contenant des groupes amino liés à un squelette carboné
• C07C 209/24 - Préparation de composés contenant des groupes amino liés à un squelette carboné par alkylation réductive, avec des composés carbonylés, d'ammoniac, d'amines ou de composés ayant des groupes réductibles en groupes amino
• C07C 211/08 - Monoamines contenant des groupes alkyle ayant un nombre différent d'atomes de carbone

Abrégé

The present invention relates to a process for producing α, β-unsaturated aldehyde compounds under relatively mild reaction conditions, i.e. at a temperature lower than 115 °C.

Classes IPC  ?

• C07C 47/20 - Composés non saturés comportant des groupes —CHO liés à des atomes de carbone acycliques
• C07C 45/00 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés

Abrégé

The invention relates to an installation intended to separate the components of a mixture containing fibres (2) and granules (3), the installation comprising a tribocharger (4) for conferring an electrostatic charge upon the components (2, 3), at least one pair of electrodes (5, 6) for generating a separating electric field that conveys the charged components, according to their polarity, to collectors (10, 11), the installation being characterized in that the tribocharger (4) has a confinement grating (14) designed to keep the components in the tribocharger (4) until the components (2, 3) have attained sufficient charge, and then allow the components, once charged, to pass into the gap (7) from where the components (2, 3) reach their collector (10, 11) under the action of the separating electric field.

Classes IPC  ?

• B03C 7/12 - Séparateurs dans lesquels le matériau tombe en chute libre
• B03C 7/10 - Séparateurs dans lesquels le matériau tombe en cascades
• B03C 7/06 - Séparateurs ayant des supports pour le matériau traité, de forme cylindrique
• B03C 7/00 - Séparation par effet électrostatique des solides mélangés

Abrégé

The invention relates to a separation method that makes it possible, starting from a mixture (1) containing fibers (2) and granules (3), to separate the fibres from the granules, said method comprising a supply step (SI), during which the mixture is transported to a receptacle (10) provided with a screen (11), a dissociation step (S2), during which the following are carried out simultaneously: an agitation substep (S201), according to which a mechanical mixing of the mixture (1) contained in the receptacle (10) is carried out, and a neutralization substep (S202), according to which the mixture that is undergoing mixing in the receptacle (10) is exposed to bipolar charges in order to neutralize electrostatic charges of the fibers (2) and of the granules (3), followed by a screening step (S3) during which the mixture (1) treated in accordance with the dissociation step (S2) is passed over the screen (11) in order to retain in the receptacle (10) a first product (PI) enriched in fibers (2) while a second product (P2) enriched in granules (3) is discharged through the screen (11).

Classes IPC  ?

• B07B 1/22 - Tambours tournants
• B07B 1/24 - Tambours tournants avec agitateurs intérieurs fixes ou mobiles
• B07B 4/06 - Séparation des solides, obtenue en soumettant leur mélange à des courants de gaz pendant que le mélange tombe en utilisant des tambours en rotation
• B07B 4/08 - Séparation des solides, obtenue en soumettant leur mélange à des courants de gaz pendant que le mélange est supporté par des cribles, des tamis ou des éléments mécaniques analogues
• B02C 23/08 - Séparation ou triage de matériaux, associé au broyage ou à la désagrégation

Abrégé

The invention relates to a reduction ratio changing device (1) for a mechanical transmission system with a chain. The reduction ratio changing device (1) comprises a toothing (2, 3). The toothing of the reduction ratio changing device (1) comprises a portion (2), referred to as helical portion, forming a toothed helix winding around an axis of revolution (5) of the reduction ratio changing device, and a portion (3), referred to as circular portion, forming a toothed flat circle, the centre of which coincides with the axis of revolution of the reduction ratio changing device. The helical portion (2) of the toothing extends from a distal end (4) of the toothing of the reduction ratio changing device (1) to the circular portion (3) of the toothing. The circular portion (3) of the toothing of the reduction ratio changing device (1) forms a proximal end (3) of the toothing of the reduction ratio changing device.

Classes IPC  ?

• B62M 9/08 - Transmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire de rapport variable utilisant une seule chaîne, courroie ou organe similaire comportant une roue, motrice ou entraînée, montée excentriquement ou de forme elliptiqueTransmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire de rapport variable utilisant une seule chaîne, courroie ou organe similaire avec une roue motrice ou entraînée expansible
• B62M 9/10 - Transmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire de rapport variable utilisant une seule chaîne, courroie ou organe similaire comportant des roues de dimensions différentes engagées sélectivement par la chaîne, la courroie ou l'organe similaire
• F16H 55/12 - Organes dentésVis sans fin le corps ou la jante étant constitués d'éléments amovibles
• B62M 9/00 - Transmissions caractérisées par l'emploi d'une chaîne sans fin, d'une courroie ou d'un organe similaire
• F16H 55/30 - Roues à chaînes

Abrégé

The invention relates to an optical element (30) comprising: - a transparent substrate (32), - an intermediate coating (38) extending over at least one main surface (36) of the substrate (32), the intermediate coating (38) comprising a plurality of dense thin layers (38a, 38b) having, alternately, a first optical index and a second optical index, the first optical index being greater than the second optical index. The optical element (30) also comprises: - at least one porous layer (42) extending over the intermediate coating (38) opposite the substrate (32), the porous layer (42) having a third optical index, the third optical index being lower than the first and second optical indices.

Classes IPC  ?

• G02B 1/115 - Multicouches
• C23C 14/22 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le procédé de revêtement

Abrégé

The present invention relates to compounds of formula (I), wherein: - A is an anti-cancer agent, - Y is an electron-withdrawing or electron-donating group, - L represents a linker -A1-A2-A3-A4-A5-A6-. A1, A3 and A5 representing a (C1-C6) alkylene radical, A2 representing a group obtained by click chemistry, A4 being a (C1-C32) alkylene radical interrupted by at least one oxygen atom, A6 being a radical selected from the group consisting of: -NRc-, -O- and -S-, Rc representing H or a (C1-C12) alkyl group, and - L' is a radical capable of reacting with an amino, hydroxy or thiol function.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif

Abrégé

12345613516241326cc11212) alkyl group, and - L' is a radical capable of reacting with an amino, hydroxy or thiol function.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells in subject and concluding that the treatment with a TKI should be discontinued when the number and/or frequency of innate CD8 T-cells is higher than the predetermined reference value. Inventors evaluated whether innate CD8(+) T-cells are an early target of CML therapy success. Among peripheral blood effector CD8(+) T-cells, inventors shown that both number nd/or frequency and functional signatures of innate CD8(+) T-cells are enhanced as early as 3 months of therapy. Strikingly, they observe that patients with high innate CD8(+) T-cell number and/or frequency at 3 months and/or diagnosis achieve a DMR earlier than patients with low innate CD8(+) T-cell number. Furthermore, a higher number and/or frequency of high innate CD8(+) T-cell patients achieved a stable DMR for over 2 years. They have also observed that the success of TKI therapy cessation is associated with higher proportion of innate CD8 T-cells expressing perforin. Collectively, these findings highlight innate CD8(+) T-cells as a potential marker for both CML therapy success and successful long-term treatment-free remission (TFR), and thus therapy discontinuation eligibility.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 31/426 - 1,3-Thiazoles
• A61P 35/00 - Agents anticancéreux

Abrégé

Tool set for placing an intersomatic implant in position, said tool set comprising a tool (1) for placing said implant in position, said tool comprising a shaft (11) for positioning said implant, an implant holder (2) and an implant holder rod (15) for holding a cage (4) of the implant, said shaft being provided with a first end (12) forming a handle and with a second end (13) fixed to said implant holder, said implant holder rod being received movably in rotation in a tubular portion (14) of said shaft and being provided with a distal end (16) passing through said implant holder in order to engage in said cage, said implant holder being provided with a stub (22) for orientation of said cage with respect to said implant holder.

Classes IPC  ?

• A61B 17/17 - Dispositifs de guidage pour les forets
• A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
• A61B 17/80 - Plaques corticales
• A61F 2/44 - Articulations pour l'épine dorsale, p. ex. vertèbres, disques intervertébraux
• A61F 2/46 - Outils particuliers pour l'implantation des articulations artificielles

Abrégé

A device forming a robotic hand, including a base forming a hand palm, at least two articulated structures each forming a robotic finger, each articulated structure being connected to the base by at least one articulation, at least one drive mechanism for each articulation, at least one actuator arranged to actuate the at least one drive mechanism by means of at least one flexible drive link connecting and driving the at least one drive mechanism, structure for measuring the pivoting of the at least one actuator and one or more of the articulations, a glove covering the base and the at least two articulated structures, the glove being closed so as to form, inside the glove, a volume filled with oil between the wall of the glove and the base and the at least two articulated structures. Robotic hands used in aquatic environments at great depths are also disclosed.

Classes IPC  ?

• B25J 15/00 - Têtes de préhension
• B25J 15/10 - Têtes de préhension avec des éléments en forme de doigts avec au moins trois éléments en forme de doigts
• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs
• B25J 19/02 - Dispositifs sensibles

Abrégé

The present invention relates to a composition comprising: - either at least ethyl-?-D-glucuronide, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-?-D-glucuronide probe) and at least ethyl-?-D-galactopyranoside (or ethyl-?-D-galactopyranoside probe), the ethyl part of which comprises at least one non-radioactive isotope; - or at least ethyl-?-mannopyranoside, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-?-D-glucuronide probe); for use thereof as a diagnostic and/or prognostic agent.

Classes IPC  ?

• C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a nickel-based superalloy comprising in weight percentages: 5.0 to 6.0% of aluminium, 6.0 to 9.0% of tantalum, 1.0 to 5.0% of cobalt, 5.0 to 7.5% of chromium, 0 to 1.0% of molybdenum, 4.0 to 6.0% of tungsten, 0.50 to 3.5% of rhenium, 1.0 to 4.0% of platinum, 0.05 to 0.25% of hafnium, 0 to 0.15% of silicon, the remainder consisting of nickel and unavoidable impurities. The invention also relates to a single-crystal blade (20A, 20B) comprising such an alloy and to a turbomachine (10) comprising such a blade (20A, 20B).

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• F01D 5/28 - Emploi de matériaux spécifiésMesures contre l'érosion ou la corrosion

Abrégé

The present invention relates to a composition comprising: - either at least ethyl-β-D-glucuronide, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-β-D-glucuronide probe) and at least ethyl-β-D-galactopyranoside (or ethyl-β-D-galactopyranoside probe), the ethyl part of which comprises at least one non-radioactive isotope; - or at least ethyl-α-mannopyranoside, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-β-D-glucuronide probe); for use thereof as a diagnostic and/or prognostic agent.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase

Abrégé

The invention relates to a method for helping to bend a rod that can be implanted in a patient, the method comprising the following steps: - acquiring one or more measurements of distance and/or angle between elements of a vertebral column of the patient; - determining a type of vertebral column of the patient, on the basis of said measurements, according to a classification; - identifying one or more invariant parameters corresponding to the determined type of vertebral column; - calculating (200, 200') one or more radii of curvature for bending a rod on the basis of the previously identified invariant parameters and the determined type of vertebral column; - obtaining a representation of the rod bent according to said one or more radii of curvature; and - displaying the representation.

Classes IPC  ?

• A61B 17/88 - Moyens ou procédés pour implanter ou pour extraire des dispositifs de fixation interne
• A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
• A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre

Abrégé

A device forming a robotic hand, including a base forming the palm of a hand, at least two articulated structures each forming a robotic finger, each articulated structure being connected to the base by at least one articulation, at least one drive mechanism for each articulation, at least one actuator designed to actuate the at least one drive mechanism at least by a flexible drive connection connecting and driving the at least one drive mechanism, at least one intermediate driveshaft for relaying the movement of the at least one actuator such that the at least one intermediate drive shaft is actuated by an actuator, and the at least one intermediate shaft is connected to at least two distinct drive mechanisms by the at least one flexible drive connection.

Classes IPC  ?

• B25J 15/00 - Têtes de préhension
• B25J 15/10 - Têtes de préhension avec des éléments en forme de doigts avec au moins trois éléments en forme de doigts
• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs

Abrégé

The invention concerns a method for manufacturing an aircraft part, the part comprising a monocrystalline nickel-based superalloy substrate, the method consecutively implementing the steps of moulding the part at a moulding temperature greater than the melting temperature of the superalloy, and cooling the part, such that the monocrystalline superalloy has a γ phase and a γ phase, solution heat treatment of the part at a first temperature between the solves temperature of the γ′ phase and the melting temperature of the superalloy, homogenising the crystalline structure or the part, cooling the part to ambient temperature, first tempering and second tempering.

Classes IPC  ?

• C22F 1/10 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid du nickel ou du cobalt ou de leurs alliages
• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome

Abrégé

The present invention relates to poor sleep issues notably in the contact of people fallen in coma. Therefore, it is desirable to be able to monitor sleep in intensive healthcare unit. However, the known methods so far requires the presence of sleep specialists, which renders the use of such monitoring method very difficult to implement. Therefore, the inventors have developed a method and a system with a reduced invasiveness and limited human intervention. The present invention relates to a specific sleep analyzer.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The inventors aim to assess IL-33 and HMGB1 contributions as alarmins to I/R injury following solid organ transplantation in particular liver transplantation. This study was conducted from a prospective biological collection and a clinical database of 40 liver transplant recipients in Tours hospital center. Serum IL-33 and HMGB1 levels were determined at graft reperfusion, at the end of the liver transplantation and at postoperative day 1 and 3. A post-reperfusion liver biopsy was systematic. Serum IL-33 increase is associated with: i) severe-moderate liver lesions; ii) an early allograft dysfunction; iii) a post-reperfusion syndrome occurrence; iv) a post liver transplantation acute kidney injury occurrence. Serum HMGB1 increase is associated with: i) an early allograft dysfunction; ii) a post-reperfusion syndrome occurrence. IL-33 and HMGB1 thus contribute as alarmins to I/R injury in human liver transplantation. Their serum levels are predictive of I/R injury severity and its clinical impact. Serum assay for IL-33 andHMGB1 upon graft reperfusion could be used as early biomarkers of early allograft function in solid organ transplantation, in particular in liver transplantation.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Device (1) for measuring at least one flow parameter of a fluid through a duct, in particular the flow rate thereof, comprising: - a portion (2) forming an obstacle, intended to be brought into contact with the flow, the shape of which being chosen so as to generate turbulence in the flow; - a vibration sensor (3) sensitive to vibrations caused on the portion (2) forming an obstacle by the turbulence; - a processing unit (5) configured to calculate the flow parameter of the fluid based on at least one vibration signal (4) delivered by the vibration sensor (3).

Classes IPC  ?

• G01F 1/32 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en utilisant des effets mécaniques par détection des effets dynamiques de l’écoulement utilisant des débitmètres à tourbillons
• G01F 1/325 - Moyens de détection de quantités utilisées comme variables de substitution corrélées à l’effet des tourbillons

Abrégé

The invention relates to a device (100) for rehabilitation or training comprising: - a movable support (102); - a first motorisation means (106) with positional control and designed to move the movable support (102); - a first force measurement means (108) designed for measuring a first torque; - a control means, characterised in that the control means is designed to control the position of the first motorisation means (106) so as to move the movable support (102) in the trajectory thereof as long as the first measured torque equals a setpoint torque and, otherwise, the control means is designed and/or programmed to slow down or stop the first motorisation means (106) in the series of positions of the movable support (102) if the first measured torque is outside said torque setpoint.

Classes IPC  ?

• A63B 24/00 - Commandes électriques ou électroniques pour les appareils d'exercice des groupes
• A63B 71/00 - Accessoires pour jeux ou sports non couverts dans les groupes

Abrégé

The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61P 27/02 - Agents ophtalmiques
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
• C07D 311/54 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre en positions 2 et 4 avec un atome d'hydrogène en position 3 substitués dans le carbocycle

Abrégé

The present invention relates to a device which can serve as a model of a hemato-encephalic barrier (HEB) comprising two compartments in which certain cell types are arranged. The invention also relates to the method for preparing said device and the use thereof as a model of the HEB.

Classes IPC  ?

• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12N 5/079 - Cellules neurales
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

Extra-corporeal membrane oxygenation (ECMO) has since been increasingly deployed, to become integral to the therapeutic arsenal of the intensive care unit for patients suffering from cardiac and/or respiratory insufficiency. The inventors endeavored to explore the potential of hemolysis index (HI) monitoring during ECMO in a retrospective study including 115 patients for which EMCO was deployed. In particular, the inventors the inventors used machine-learning algorithms to build a decisional tree including the HI level as a predictive factor for patients under ECMO. Thus the present invention relates to use of algorithms for predicting survival of a patient having extracorporeal membrane oxygenation.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p. ex. adaptation de la température, irradiation
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• A61M 1/16 - Systèmes de dialyseReins artificielsOxygénateurs du sang avec membranes

Abrégé

Injection device (2) for a heat engine (6), comprising: - a flowmeter or a pressure or speed sensor (3) designed to be positioned in or in communication with an intake manifold (4) and designed and/or programmed to provide a measurement (16) which depends on an air flow circulating in the intake manifold, - a control unit (5) designed and/or programmed to control a fuel injection, characterised in that the control unit is designed and/or programmed to receive and analyse the measurement from the flowmeter, or from the pressure sensor or from the speed sensor, and, depending on the measurement, compute a command (17) designed to control a fuel injector (7) so as to control the injection of an amount of fuel which depends on the measurement.

Classes IPC  ?

• F02D 41/18 - Dispositions de circuits pour produire des signaux de commande en mesurant le débit d'admission d'air
• F02D 41/34 - Commande de l'injection de combustible du type à basse pression avec des moyens pour commander la synchronisation ou la durée de l'injection
• F02D 41/40 - Commande de l'injection de combustible du type à haute pression avec des moyens pour commander la synchronisation ou la durée de l'injection

Abrégé

The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells in subject and concluding that the treatment with a TKI should be discontinued when the number and/or frequency of innate CD8 T-cells is higher than the predetermined reference value. Inventors evaluated whether innate CD8(+) T-cells are an early target of CML therapy success. Among peripheral blood effector CD8(+) T-cells, inventors shown that both number and/or frequency and functional signatures of innate CD8(+) T-cells are enhanced as early as 3 months of therapy. Strikingly, they observe that patients with high innate CD8(+) T-cell number and/or frequency at 3 months and/or diagnosis achieve a DMR earlier than patients with low innate CD8(+) T-cell number. Furthermore, a higher number and/or frequency of high innate CD8(+) T-cell patients achieved a stable DMR for over 2 years. They have also observed that the success of TKI therapy cessation is associated with higher proportion of innate CD8 T-cells expressing perforin. Collectively, these findings highlight innate CD8(+) T-cells as a potential marker for both CML therapy success and successful long-term treatment-free remission (TFR), and thus therapy discontinuation eligibility.

Classes IPC  ?

• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a nickel-based superalloy comprising, in percentages by mass, 5.0 to 6.0% aluminum, 6.0 to 9.5% tantalum, 0 to 1.50% titanium, 8.0 to 10.0% cobalt, 6.0 to 7.0% chromium, 0.30 to 0.90% molybdenum, 5.5 to 6.5% tungsten, 0 to 2.50% rhenium, 0.05 to 0.15% hafnium, 0.70 to 4.30% platinum, 0 to 0.15% silicon, the remainder being nickel and unavoidable impurities. The invention also relates to a single-crystal blade comprising such an alloy and a turbomachine comprising such a blade.

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• C30B 29/52 - Alliages
• F01D 5/28 - Emploi de matériaux spécifiésMesures contre l'érosion ou la corrosion

Abrégé

The present invention relates to a device (1) forming a robotic hand, comprising: - a base forming a hand palm, - at least two articulated structures each forming a robotic finger, each articulated structure being connected to the base by at least one articulation, - at least one drive mechanism for each articulation, - at least one actuator arranged to actuate the at least one drive mechanism by means of at least one flexible drive link connecting and driving the at least one drive mechanism, - means for measuring the pivoting of the at least one actuator and one or more of the articulations, - a glove (102) covering the base and the at least two articulated structures, the glove being closed so as to form, inside the glove, a volume filled with oil between the wall of the glove and the base and the at least two articulated structures. The field of the invention is, in particular, that of robotic hands used in aquatic environments at great depths.

Classes IPC  ?

• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs
• B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p. ex. à la vue ou au toucher
• B25J 15/00 - Têtes de préhension
• B25J 19/00 - Accessoires adaptés aux manipulateurs, p. ex. pour contrôler, pour observerDispositifs de sécurité combinés avec les manipulateurs ou spécialement conçus pour être utilisés en association avec ces manipulateurs

Abrégé

A method of producing benzene derivatives from furfural and its derivatives. Provided are routes for converting furfural and its derivatives into benzene derivatives including its intermediates.

Classes IPC  ?

• C07C 2/50 - Réaction de Diels-Alder
• C07C 69/75 - Esters d'acides carboxyliques dont un groupe carboxyle est lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons d'acides avec un cycle à six chaînons

Abrégé

The present invention relates to a method and a device for the electrostatic separation of granular mixtures of millimetric or sub-millimetric size, which are composed of non-conductive particles, non-conductive and conductive particles and conductive particles, simultaneously using the electric field E, aerodynamic force and gravity. Said forces are exerted on the particles which are previously charged in an intense electric field E generated by a DC voltage applied to two coaxial cylinders, that constitute electrodes. A mechanical cleaning system detaches the particles from the surface of the electrodes, and facilitates the recovery thereof in a collection system, under the action of cyclone vacuums, in such a way that the cleaning of the electrodes and the collection of the separated particles is continuously performed.

Classes IPC  ?

• B03C 7/06 - Séparateurs ayant des supports pour le matériau traité, de forme cylindrique
• B03C 7/12 - Séparateurs dans lesquels le matériau tombe en chute libre
• B03C 7/00 - Séparation par effet électrostatique des solides mélangés

Abrégé

The present invention relates to a device forming a robotic hand, comprising: - a base forming the palm of a hand, - at least two articulated structures each forming a robotic finger, each articulated structure being connected to the base by at least one articulation, - at least one drive mechanism for each articulation, - at least one actuator designed to actuate the at least one drive mechanism at least by means of a flexible drive connection connecting and driving the at least one drive mechanism, - at least one intermediate driveshaft for relaying the movement of the at least one actuator such that: - the at least one intermediate drive shaft is actuated by an actuator, and - the at least one intermediate shaft is connected to at least two distinct drive mechanisms by means of the at least one flexible drive connection. The field of the invention is particularly that of robotic hands.

Classes IPC  ?

• B25J 15/00 - Têtes de préhension
• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs

Abrégé

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• C07K 14/54 - Interleukines [IL]
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a process for preparing a polymer/biological entities alloy, comprising a step of mixing a polymer and biological entities that degrade it, during a heat treatment, said heat treatment being performed at a temperature T above room temperature and said biological entities being resistant to said temperature T, characterized in that said biological entities are chosen from enzymes that degrade said polymer and microorganisms that degrade said polymer.

Classes IPC  ?

• C08J 3/00 - Procédés pour le traitement de substances macromoléculaires ou la formation de mélanges
• C08J 3/20 - Formation de mélanges de polymères avec des additifs, p. ex. coloration
• C12N 9/14 - Hydrolases (3.)
• C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
• C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p. ex. lactones
• C12N 9/20 - Scission des triglycérides, p. ex. au moyen de lipase
• C12N 9/58 - Protéinases provenant de champignons
• C12N 11/18 - Systèmes multi-enzymatiques
• C12N 11/098 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique le support étant un polymère synthétique formé en présence des enzymes ou des cellules microbiennes
• C12N 11/096 - PolyestersPolyamides
• C08K 5/00 - Emploi d'ingrédients organiques

Abrégé

The invention concerns a method for manufacturing an aircraft part, the part comprising a monocrystalline nickel-based superalloy substrate, the method consecutively implementing the steps of moulding the part at a moulding temperature greater than the melting temperature of the superalloy, and cooling the part, such that the monocrystalline superalloy has a γ phase and a γ' phase, solution heat treatment of the part at a first temperature between the solvus temperature of the γ' phase and the melting temperature of the superalloy, homogenising the crystalline structure of the part, cooling the part to ambient temperature, first tempering and second tempering.

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• C22F 1/10 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid du nickel ou du cobalt ou de leurs alliages
• C30B 33/02 - Traitement thermique

Abrégé

The present invention relates to specific binding proteins, such as antibodies which bind specifically to oncostatin M (OSM), in particular human OSM (hOSM), and which modulate the interaction between oncostatin M and gp130 and/or the LIF receptor. The invention also relates to pharmaceutical compositions and to uses thereof in the prevention and/or treatment of diseases associated with an abnormal level of oncostatin M and in particular inflammatory skin diseases and cancer. The invention also relates to diagnostic compositions and to uses thereof in the detection of diseases associated with an abnormal level of oncostatin M and/or diseases associated with an abnormal level of oncostatin M receptors, and in particular inflammatory skin diseases and cancer.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 17/06 - Antipsoriasiques

Abrégé

for example wild-type CFTR proteinfor example human cystic fibrosis bronchoepithelial cells carrying CFTR mutationin vitroin vivoin vitroin vitro use comprising said myelinosomes and pharmaceutical compositions comprising said myelinosomes. Figure: none

Classes IPC  ?

• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
• A61K 9/50 - Microcapsules
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Acute kidney injury (AKI) is a related to chronic kidney disease and death in patients from the general population, with or without type 2 diabetes. Nevertheless AKI biomarkers are rarely validated in diabetes population. The inventors aimed to explore the individual and combined prognostic value of 7 circulating candidate markers for AKI. This include markers of cardiac and endothelial dysfunction (mid-regional-pro-adrenomedullin [MRproADM], angiopoietinlike-2 [ANGPTL2], N-terminal prohormone brain natriuretic peptide [NTproBNP]) oxidative stress (fluorescent advanced glycation endproducts [AGE], carbonyls), cardio-renal pathways (copeptin [CTproAVP]), and inflammation (soluble TNF receptor 1 [TNFR1]). They prospectively followed-up 1345 (565 women/780 men) type 2 diabetes participants of a French single-centre hospital-based cohort (SURDIAGENE). In univariate analysis, each biomarker was significantly associated with AKI, and 6 remained associated after multivariable adjustment. The addition of a multimarker score summing standardized and weighted values of these 6 markers to the model including usual risk factors significantly improved C-statistics (0.724 to 0.759, P<0.0001), and 5-year risk-predictive performance (relative integrated discrimination improvement index=0.435, P<0.0001). Thus the panel of 6 biomarkers representing cardiac, vascular and inflammatory pathways improves the prediction of AKI over usual risk factors in patients with type 2 diabetes.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

233 and C.

Classes IPC  ?

• C07C 211/03 - Monoamines
• C07C 209/60 - Préparation de composés contenant des groupes amino liés à un squelette carboné par des réactions de condensation ou d'addition, p. ex. réaction de Mannich, addition d'ammoniac ou d'amines à des alcènes ou à des alcynes ou addition de composés, contenant un atome d'hydrogène actif, à des bases de Schiff, à des quinone-imines ou à des aziranes
• B01J 23/46 - Ruthénium, rhodium, osmium ou iridium

Abrégé

A process for the reductive amination of an α,β-unsaturated carbonyl compound and a process for the preparation of a tetrathydrofuran-derived amine starting from furfural or a derivative thereof.

Classes IPC  ?

• C07C 209/26 - Préparation de composés contenant des groupes amino liés à un squelette carboné par alkylation réductive, avec des composés carbonylés, d'ammoniac, d'amines ou de composés ayant des groupes réductibles en groupes amino par réduction avec de l'hydrogène
• C07D 307/06 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle

Abrégé

The invention relates to a process for the reductive amination of a carbonyl compound. The invention furthermore relates to a process for the preparation of a furan-derived amine starting from furfural or a derivative thereof.

Classes IPC  ?

• C07D 209/00 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle
• C07D 307/52 - Radicaux substitués par des atomes d'azote ne faisant par partie d'un radical nitro
• C07D 307/46 - Atomes d'oxygène liés par des liaisons doubles ou deux atomes d'oxygène liés par des liaisons simples au même atome de carbone

Abrégé

EnterobacteriaceaeE.coliE.coliE.coli, allowing using low colistin concentrations, while, preventing bacterial regrowth. Thus the present invention relates to use of acyclic terpene alcohols for enhancing the antimicrobial activity of colistin.

Classes IPC  ?

• A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
• A61K 38/12 - Peptides cycliques
• A61K 9/51 - Nanocapsules
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/04 - Agents antibactériens

Abrégé

Inflammation and oxidative stress play an important role in the pathogenesis of lower- extremity artery disease (LEAD). The inventors assessed the prognostic values of inflammatory and redox status biomarkers on the risk of LEAD in individuals with type 2 diabetes. In particular, plasma concentrations of TNF receptor-1 (TNFR1) and ischemia-modified albumin (IMA) were measured at baseline in the SURDIAGENE (SURvie, DIAbete de type 2 et GENEtique) cohort. High plasma concentrations of TNFR1 (HR [95%CI] for second versus first tertile and IMA (2.42 [1.38–4.23], p=0.002; 2.04 [1.17–3.57], p=0.01) were independently associated with increased risk of major LEAD. Plasma concentrations of TNFR1, but not IMA, yielded incremental information, over traditional risk factors, for the risk of major LEAD: c-statistic change (0.036 [0.013–0.059], p=0.002), IDI (0.012 [0.005–0.022], p<0.001), continuous NRI (0.583 [0.294–0.847], p<0.001), and categorical NRI (0.171 [0.027–0.317], p=0.02). In conclusion, this is the first report of independent associations between high plasma TNFR1 and/or IMA concentrations and increased 5.6-year risk of major LEAD in people with type 2 diabetes.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a nickel-based superalloy comprising in weight percentages: 5.0 to 6.0 % of aluminum, 6.0 to 9.5 % of tantalum, 0 to 1.50 % of titanium, 8.0 to 10.0 % of cobalt, 6.0 to 7.0 % of chromium, 0.30 to 0.90 % of molybdenum, 5.5 to 6.5 % of tungsten, 0 to 2.50 % of rhenium, 0.05 to 0.15 % of hafnium, 0.70 to 4.30 % of platinum, 0 to 0.15 % of silicon, the remainder being nickel and inevitable impurities. The invention also relates to a single-crystal blade (20A, 20 B) comprising such an alloy and to a turbomachine (10) comprising such a blade (20A, 20 B).

Classes IPC  ?

• C22C 19/05 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel avec du chrome
• C30B 1/00 - Croissance des monocristaux à partir de l'état solide
• F01D 5/28 - Emploi de matériaux spécifiésMesures contre l'érosion ou la corrosion

Abrégé

A process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol with at least one other alcohol in the presence of water and at least one catalyst, said furfuryl alcohol being present in a quantity of at least 5% by weight, based on the total weight of the alcohols, and said catalyst comprising at least one triflate ligand and at least one metal selected from bismuth, gallium, aluminum, tin and iron.

Classes IPC  ?

• C07C 67/29 - Préparation d'esters d'acides carboxyliques par modification de la partie hydroxyle de l'ester sans introduction d'un groupe ester par introduction de groupes fonctionnels contenant de l'oxygène
• C07C 69/716 - Esters d'acides céto-carboxyliques
• B01J 31/22 - Complexes organiques

Abrégé

The invention relates to a non-destructive device for measuring alpha and/or beta radiation emitted by a flat surface of a solid. The device comprises at least one measuring head and a motorised automaton configured to move a measuring head and bring it into contact with the flat surface. The measuring head comprises: - at least one primary solid scintillator having a main planar surface intended to be brought into contact with a portion of the flat surface; - at least one silicon photomultiplier (SiPM), each SiPM being optically coupled to a primary solid scintillator; - a housing opaque to visible light and to alpha and beta radiation, having an open recess intended to house the at least one primary solid scintillator and the at least one SiPM, the primary solid scintillator being arranged to close the recess and form an outer wall of the housing, so as to allow the primary scintillator to be brought into contact with the portion of surface.

Classes IPC  ?

• G01T 1/169 - Exploration, localisation de surfaces contaminées
• G01T 7/00 - Détails des instruments de mesure des radiations

Abrégé

The present invention relates to a method and a device for the electrostatic separation of granular mixtures of millimetric or sub-millimetric size, which are composed of non-conductive particles (11a, 11b), non-conductive (11) and conductive (12) particles and conductive particles (12a, 12b), simultaneously using the electric field E, aerodynamic force and gravity. Said forces are exerted on the particles (11, 11a, 11b, 12, 12a, 12b) which are previously charged in an intense electric field E generated by a DC voltage applied to two coaxial cylinders 221, 222 that constitute electrodes. A mechanical cleaning system detaches the particles 11a and 11b or 11 and 12 or 12a and 12b from the surface of the electrodes 221, 222 and facilitates the recovery thereof in a collection system 23, under the action of cyclone vacuums, in such a way that the cleaning of the electrodes and the collection of the separated particles is continuously performed.

Classes IPC  ?

• B03C 7/12 - Séparateurs dans lesquels le matériau tombe en chute libre

Abrégé

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 27/02 - Agents ophtalmiques
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
• C07D 311/54 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre en positions 2 et 4 avec un atome d'hydrogène en position 3 substitués dans le carbocycle

Abrégé

γγ/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IL-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale

Abrégé

The invention concerns a mechanical device (100) for transmitting rotational movement about an axis of rotation (106), referred to as the main axis of rotation, from a first segment to a second segment of a robot, said device (100) comprising: - a first assembly (102) intended to be attached to said first segment, - a second assembly (104) intended to be attached to said second segment, - a drive means (108) between said assemblies (102,104); characterised in that, on the side of one of said assemblies (104), said drive means (108) is linked to said assembly (104) by a connection interface (110) that is able to rotate elastically about an axis of rotation (112), referred to as the secondary axis of rotation, that is stationary with respect to said assembly (104), allowing said drive means (108) to rotate with respect to said assembly (104).

Classes IPC  ?

• B25J 17/02 - Joints articulés
• B25J 19/06 - Dispositifs de sécurité
• F16D 3/50 - Accouplements extensibles, c.-à-d. avec moyens permettant le mouvement entre parties accouplées durant leur entraînement avec pièces d'accouplement reliées par un ou plusieurs organes intermédiaires

Abrégé

The present invention relates to a method for preparing at least one oligosaccharide, comprising a step of ultrasound irradiation, at a frequency higher than 100 kHz, of an alcohol composition comprising at least one saccharide monomer and at least one monoalcohol ROH, R being an alkyl chain comprising 1 to 24 carbon atoms.

Classes IPC  ?

• C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
• C07H 1/00 - Procédés de préparation des dérivés du sucre
• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés

Abrégé

The present invention concerns a device that can serve as a hemato-encephalitic barrier (HEB) model comprising two compartments in which certain cell types are arranged. The invention also concerns a method for preparing said device and its use as an HEB model.

Classes IPC  ?

• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores

Abrégé

The present invention relates to a medical device (1) for applying pressure to a joint segment of a human body, to a corresponding system and to associated uses. The device (1) comprises at least three bearing units (5) intended to be attached to a holder (90), each bearing unit (5) having: an extendable arm (10); a force-measuring means (20) attached to said extendable arm (10); a movement-measuring means (30); a bearing element (40) which is attached to the distal portion of said extendable arm (10), is adapted to be in contact with a part of the human body and makes it possible to apply said force measured by said force-measuring means (20) to said part of the human body; and an attachment means (60) adapted to attach said bearing unit (5) to said holder (90).

Classes IPC  ?

• A61B 6/04 - Mise en position des patientsLits inclinables ou similaires
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 90/14 - Fixateurs pour parties du corps, p. ex. clamps crâniensDétails de construction des fixateurs, p. ex. broches
• A61G 13/12 - Appuis qui leur sont spécialement adaptésDisposition des surfaces pour supporter des patients

Abrégé

A device for penetrating into a fluid, comprising at least one profile (10), a fluid injector (14), a means for measuring the separation of the flow (18) along the profile, downstream of the injector, and an injector activity controller (12) designed to: - store measurements y(t) over time t of the flow separation measurement means, - send, and store instructions u(t)= 0 or 1 over time t of inactivity or activity respectively of the injector, - calculate a quantity σ(t) dependent on quantities y(t), u(t), and on various received parameters, then compare same to a parameter σ* depending on the received parameters and a target value of the flow separation measurement means, and then deduce an activation or deactivation of the injector.

Classes IPC  ?

• F15D 1/00 - Action sur l'écoulement des fluides
• F15B 21/08 - Systèmes de servomoteur comportant des moyens de commande actionnés électriquement
• B64C 21/04 - Moyens permettant d'influencer l'écoulement d'air sur les surfaces des aéronefs en agissant sur la couche limite par utilisation de fentes, de conduits, de surfaces poreuses ou de dispositifs similaires en vue du soufflage
• G05B 13/02 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques

Abrégé

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• C07D 471/04 - Systèmes condensés en ortho
• A01N 1/02 - Conservation de parties vivantes
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

Some embodiments are directed to a method for detecting harmonic pollution in an electrical distribution network carrying a three-phase current, including a step of measuring the voltages and strengths of the current, for each of said phases, at a counting point of the network; a step of calculating a first quaternion impedance corresponding to the fundamental frequency of the current; a step of calculating at least one second quaternion impedance corresponding to a harmonic frequency of the current, these impedances being calculated by converting the voltages and strengths in a two-dimensional frame of reference defined according to an angle that is dependent on said frequency in order to provide a system of two vectors of three quantities, ud, uq, uo and id, iq, io, respectively.

Classes IPC  ?

• G01R 27/26 - Mesure de l'inductance ou de la capacitanceMesure du facteur de qualité, p. ex. en utilisant la méthode par résonanceMesure de facteur de pertesMesure des constantes diélectriques
• H02J 3/01 - Dispositions pour réduire les harmoniques ou les ondulations
• G01R 27/16 - Mesure de l'impédance d'un élément ou d'un réseau dans lequel passe un courant provenant d'une autre source, p. ex. câble, ligne de transport de l'énergie
• H02J 13/00 - Circuits pour pourvoir à l'indication à distance des conditions d'un réseau, p. ex. un enregistrement instantané des conditions d'ouverture ou de fermeture de chaque sectionneur du réseauCircuits pour pourvoir à la commande à distance des moyens de commutation dans un réseau de distribution d'énergie, p. ex. mise en ou hors circuit de consommateurs de courant par l'utilisation de signaux d'impulsion codés transmis par le réseau

Abrégé

Disclosed is a medico-surgical simulator and to a corresponding method. The medico-surgical simulator includes a vascularization device and/or a ventilation device, as well as a regulation device. The medico-surgical simulator is arranged so as to be connected to a cadaver and to vascularize an arterial system of the cadaver via the vascularization device and/or to ventilate a respiratory system of the cadaver via the ventilation device. The regulation device controls the vascularization and ventilation devices in such a way as to simulate cardiorespiratory functions for providing surgical training carried out on the cadaver with a very high degree of realism.

Classes IPC  ?

• G09B 23/30 - Modèles anatomiques
• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine

Abrégé

The invention relates to a system for generating electric power, comprising: an alternator (1) for coupling with a drive system (7), supplying an AC voltage to an output bus (10); a reversible AC/DC converter (2) in which the AC bus (6) is connected to the output bus (10) of the alternator (1); an electricity-storage element (3) connected to the DC bus (9) of the converter (2); a controller (4) arranged to react to a transient state of load-shedding or charging impact by controlling the converter (2) so as to collect energy on the output bus (10) of the alternator (2) and to store same in the storage element (3) in the case of load-shedding, and to collect energy in the storage element (3) and to inject same into the output bus (10) in the case of charging impact, the converter (2) being controlled so as to inject currents to compensate for harmonic currents into the AC bus (10) of the alternator (1).

Classes IPC  ?

• H02M 1/12 - Dispositions de réduction des harmoniques d'une entrée ou d'une sortie en courant alternatif
• H02J 3/18 - Dispositions pour réglage, élimination ou compensation de puissance réactive dans les réseaux
• H02J 3/32 - Dispositions pour l'équilibrage de charge dans un réseau par emmagasinage d'énergie utilisant des batteries avec moyens de conversion
• H02M 7/72 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continuTransformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif avec possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande
• H02M 3/158 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs avec commande automatique de la tension ou du courant de sortie, p. ex. régulateurs à commutation comprenant plusieurs dispositifs à semi-conducteurs comme dispositifs de commande finale pour une charge unique
• H02M 7/48 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande

Abrégé

The invention relates to a solid energetic composition comprising at least one oxidizing charge and at least one nanostructured material essentially consisting of boron, said material being in amorphous form and comprising clusters of boron nanoparticles, to the process for preparing same, to a propellant comprising such a solid energetic composition and also to the uses of said composition and of said propellant, in particular in the field of space propulsion, in the motor vehicle field, in particular in airbag inflation systems or any other gas-generating system, including protective gas-generating systems, or in the field of generating high pressures for the manufacture of materials, for example for the manufacture of diamond.

Classes IPC  ?

• C06B 45/00 - Compositions ou produits définis par une structure ou des dispositions particulières des composants ou du produit
• C06B 47/10 - Compositions dans lesquelles les composants sont conservés séparément jusqu'au moment de l'explosion ou de la combustion, p. ex. explosifs du type "Sprengel"Suspensions d'un composant solide dans une phase liquide normalement non explosive, y compris une phase aqueuse épaissie les composants comportant un propergol binaire un composant contenant du bore libre, un borane organique ou un composé binaire du bore, excepté avec l'oxygène
• C06D 5/06 - Production de gaz sous pression, p. ex. pour cartouches de mine, cartouches de mise à feu, fusées par réaction de plusieurs solides

Abrégé

The present invention is directed to a process for synthesizing at least one levulinate ester, said process comprising a step of introducing furfuryl ether into a reaction medium and a step of conversion of furfuryl ether into levulinate ester in the presence of water and at least one catalyst, said catalyst comprising at least one metal selected from bismuth, gallium, aluminum, tin and iron.

Classes IPC  ?

• C07C 51/373 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par des réactions ne créant pas de groupes carboxyle par introduction de groupes fonctionnels contenant l'oxygène lié uniquement par une double liaison
• C07C 59/185 - Composés saturés ne comportant qu'un groupe carboxyle et contenant des groupes cétone
• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• C07C 69/716 - Esters d'acides céto-carboxyliques

Abrégé

Provided is a process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol with at least one other alcohol in the presence of water and at least one catalyst, said furfuryl alcohol being present in a quantity of at least 5% by weight,based on the total weight of the alcohols,and said catalyst comprising at least one metal selected from bismuth and gallium.

Classes IPC  ?

• C07C 69/716 - Esters d'acides céto-carboxyliques
• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• B01J 27/125 - HalogènesLeurs composés avec du scandium, de l'yttrium, de l'aluminium, du gallium, de l'indium ou du thallium
• B01J 23/16 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe de l'arsenic, de l'antimoine, du bismuth, du vanadium, du niobium, du tantale, du polonium, du chrome, du molybdène, du tungstène, du manganèse, du technétium ou du rhénium
• B01J 23/08 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du gallium, de l'indium ou du thallium

Abrégé

The present invention is directed to a process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol with at least one other alcohol in the presence of water and at least one catalyst, said furfuryl alcohol being present in a quantity of a least 5％ by weight, based on the total weight of the alcohols, and said catalyst comprising at least one metal selected from bismuth and gallium.

Classes IPC  ?

• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• C07C 69/716 - Esters d'acides céto-carboxyliques

Abrégé

The present invention is directed to a process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol with at least one other alcohol in the presence of water and at least one catalyst, said furfuryl alcohol being present in a quantity of a least 5％by weight, based on the total weight of the alcohols, and said catalyst comprising at least one triflate ligand and at least one metal selected from bismuth, gallium, aluminum, tin and iron.

Classes IPC  ?

• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• C07C 69/716 - Esters d'acides céto-carboxyliques

Abrégé

The present invention is directed to a process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol polymer with at least one other alcohol in the presence of water and at least one catalyst, said catalyst comprising at least one metal selected from bismuth, gallium, aluminum, tin and iron and said furfuryl alcohol polymer being obtainable by condensation of furfuryl alcohol at a temperature of at least 50℃.

Classes IPC  ?

• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• C07C 69/716 - Esters d'acides céto-carboxyliques

Abrégé

Provided is a process for synthesizing at least one levulinate ester, said process comprising the reaction of furfuryl alcohol with at least one other alcohol in the presence of water and at least one catalyst, said furfuryl alcohol being present in a quantity of at least 5% by weight, based on the total weight of the alcohols, and said catalyst comprising at least one triflate ligand and at least one metal selected from bismuth, gallium, aluminum, tin and iron.

Classes IPC  ?

• C07C 69/716 - Esters d'acides céto-carboxyliques
• C07C 67/00 - Préparation d'esters d'acides carboxyliques
• B01J 21/02 - Bore ou aluminiumLeurs oxydes ou hydroxydes
• B01J 23/08 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du gallium, de l'indium ou du thallium
• B01J 23/14 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du germanium, de l'étain ou du plomb
• B01J 23/16 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe de l'arsenic, de l'antimoine, du bismuth, du vanadium, du niobium, du tantale, du polonium, du chrome, du molybdène, du tungstène, du manganèse, du technétium ou du rhénium
• B01J 23/745 - Fer

Abrégé

The invention relates to a method for producing a structure (30) intended for forming an interface (44) between an electrode (41, 42) and an electrolyte (43) of a supercapacitor (40), comprising at least one sheet of oxidised graphene doped with nitrogen and phosphorus groups and oxygen groups (31). First, an aqueous suspension (1) of a graphene oxide is prepared in water, to which is added a nitrogen-based compound (2). The aqueous solution is heated and then filtered in order to obtain a solid compound (20) comprising oxidised graphene doped with nitrogen. Next, an acid suspension (3) comprising the solid compound and a phosphoric acid (4) is prepared, and then heated and filtered in order to obtain a structure comprising at least one sheet of oxidised graphene doped with nitrogen and comprising phosphorus groups and oxygen groups.

Classes IPC  ?

• H01G 11/26 - Électrodes caractérisées par leur structure, p. ex. multicouches, selon la porosité ou les caractéristiques de surface
• H01G 11/36 - Nanostructures, p. ex. nanofibres, nanotubes ou fullerènes
• H01G 11/86 - Procédés de fabrication de condensateurs hybrides ou EDL ou de leurs composants spécialement adaptés pour les électrodes
• C01B 32/194 - Post-traitement
• C01B 32/198 - Oxyde de graphène
• C01B 32/184 - Préparation
• C01B 32/192 - Préparation par exfoliation à partir d’oxydes graphitiques

Abrégé

This invention relates to inhalable microparticles loaded with a fluoroquinolone/metal cation complex for the treatment of respiratory diseases.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/50 - Microcapsules
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine

Abrégé

The present invention comprises the transformation of food-grade sugars containing D-fructose into caramels with an enriched content of oligosaccharides having a prebiotic activity, by using carbon dioxide as the catalyst, alone or in combination with a food-grade acid such as acetic acid, citric acid or phosphoric acid in a homogeneous medium, in a process that does not require a separation step and does not produce any waste. The resulting caramel exhibits prebiotic properties, promoting the development of a beneficial intestinal flora, and has a reparative effect on the damaged colon.

Classes IPC  ?

• A23G 3/32 - Procédés pour la préparation du caramel ou des couleurs en sucre
• B01J 38/40 - Traitement avec un gaz contenant de l'oxygène libre et avec formation de sous-produits utilisables

Abrégé

The invention concerns a method for decontaminating a catalyst contaminated with carbon, characterised in that it is implemented at ambient temperature and in that it comprises the following steps: a) providing a reactor comprising at least two electrodes separated from each other, between which a dielectric material is positioned; b) positioning said contaminated catalyst at the surface of said dielectric material; c) circulating an oxidising gas between said electrodes, said gas comprising oxygen; and d) applying an electric field between said electrodes so as to ionise said oxidising gas and form radicals and/or ionised molecules and/or metastable molecules capable of reacting with the carbon of said catalyst, said electric field inducing the deposition of a minimum power of 8 W on said dielectric material.

Classes IPC  ?

• B01J 38/12 - Traitement avec un gaz contenant de l'oxygène libre
• B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
• B01J 29/90 - Régénération ou réactivation

Abrégé

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I)for organs preservation.

Classes IPC  ?

• C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
• C07D 311/54 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre en positions 2 et 4 avec un atome d'hydrogène en position 3 substitués dans le carbocycle
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine

Abrégé

The present invention relates to methods and kits for predicting the risk of loss of renal function in patients with type 2 diabetes. The inventors explored the prognostic value of 3 circulating candidate biomarkers in patients: mid-regional-pro-adrenomedullin (MR- proADM), soluble tumor necrosis factor receptor 1 (sTNFR1), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) for change in renal function in patients with type 2 diabetes. The combination of all 3 biomarkers yielded the highest discrimination. In particular the present invention relates to a method of predicting the risk of loss of renal function in a patient with type 2 diabetes comprising determining the levels of MR-proADM, sTNFR1 and NT-proBNP in a blood sample from the patient.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a new isolated polypeptide comprising an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to the full length amino acid sequence set forth in SEQ ID NO:1, and having a polyester degrading activity, and uses thereof.

Classes IPC  ?

• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 1/20 - BactériesLeurs milieux de culture
• C12P 7/62 - Esters d’acides carboxyliques
• C12P 7/42 - Acides hydroxycarboxyliques
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
• C12P 21/04 - Peptides ou polypeptides cycliques ou pontés, p. ex. bacitracine
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
• C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation
• C12P 7/56 - Acide lactique

Abrégé

The present invention relates to methods and compositions for the preservation of organs. The inventors showed that therapeutic intervention during cold ischemia could significantly alter outcome, suggesting active mechanisms taking place. More particularly, the inventors demonstrated that Unfolded Protein Response could be a critical pathway underlying the relationship between cold ischemia time and graft outcome, highlighting the potential for UPR-based therapeutics to improve transplantation efficiency. In particular, the present invention relates to an activator of PERK-ATF4 pathway, an inhibitor of the ATF6 pathway and an inhibitor of the RNase activity of IRE1α for use in the maintain of organ viability during cold ischemia.

Classes IPC  ?

• A01N 1/02 - Conservation de parties vivantes

Abrégé

This invention relates to PLGA microparticles loaded with a fluoroquinolone with high mucosal permeability, the method of preparation thereof and applications thereof.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques

Abrégé

The invention relates to a plastic compound comprising at least one polyolefin and a biological entity that degrades said polyolefin. The invention further relates to a process for preparing a plastic article wherein at least one polyolefin and one biological entity that degrades said polyolefin are mixed at a temperature at which the polyolefin is in a partially or totally molten state.

Classes IPC  ?

• C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
• C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)

Abrégé

The present invention relates to methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons. The 10 inventors showed that interleukin 33 promotes axonal outgrowth of embryonic cortical neurons grafted into injured adult motor cortex. Moreover, they explore the effects of transplanted cells on the host local inflammatory environment in order to understand the extent to which inflammation following cortical lesion could influence the survival of grafted neurons and the development of their projections. In particular, the present invention relates 15 to ST2 agonist for use in the treatment of neuropathological disorders characterized by a loss of cortical neurons in a subject in need thereof.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention relates to methods for the treatment of viral infections by pulmonary delivery of oseltamivir carboxylate. The inventors demonstrated in rats that much higher oseltamivir acid epithelial lining fluid than plasma concentrations may be obtained by direct nebulization of this active moiety, which may present a potentially major interest for the treatment of pulmonary infections due to influenza A and B viruses In particular, the present invention relates to a method of treating an infection caused by an orthomyxovirus in a subject in need thereof comprising administering by pulmonary delivery to the subject a therapeutically effective amount of oseltamivir carboxylate.

Classes IPC  ?

• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 31/12 - Antiviraux

Abrégé

The invention concerns a device forming a robotic finger comprising a base (100) forming a palm, at least one knuckle (500, 700, 900) articulated on the base (100) about two separate joints (200, 400) non-parallel to each other, at least two actuators (110, 120, 130, 140) and cable-linking means (112, 122) respectively linking the two actuators (110, 120) to drive elements of said two joints (200, 400), characterized in that the device comprises guide means (150, 151, 152) designed to guide the cables involved in the control of each joint (400, 600, 800) located after the first joint (200) on the base (100), in a common plane passing through the axis (202) of said first joint (200).

Classes IPC  ?

• B25J 17/00 - Joints
• B25J 17/02 - Joints articulés
• B25J 18/00 - Bras
• B25J 9/10 - Manipulateurs à commande programmée caractérisés par des moyens pour régler la position des éléments manipulateurs
• B25J 15/00 - Têtes de préhension

Abrégé

The invention relates to a medico-surgical simulator and to a corresponding method. The medico-surgical simulator according to the invention comprises a vascularisation device (1) and/or a ventilation device (2), as well as a regulation device (3). The medico-surgical simulator according to the invention is arranged so as to be connected to a cadaver and to vascularise an arterial system of said cadaver via the vascularisation device (1) and/or to ventilate a respiratory system of said cadaver via the ventilation device (2). The regulation device (3) controls the vascularisation (1) and ventilation (2) devices in such a way as to simulate cardiorespiratory functions for providing surgical training carried out on the cadaver with a very high degree of realism.

Classes IPC  ?

• G09B 23/30 - Modèles anatomiques

Abrégé

The invention relates to a system (IMUROW) for determining the power (PROW) produced by a rower, said system (IMUROW) comprising at least one oar or paddle (OAR), said at least one oar (OAR) comprising a first inertial unit (IMU1) and a second inertial unit (IMU2), the said oar (OAR) collaborating with a craft (BOAT) which comprises a third inertial unit (IMU3), the system further comprising a module (COMP) for calculating a power (PROW) developed on a blade of said at least one oar (OAR).

Classes IPC  ?

• A63B 24/00 - Commandes électriques ou électroniques pour les appareils d'exercice des groupes
• A63B 69/06 - Appareils d'entraînement ou appareils destinés à des sports particuliers pour canotage ou aviron

Abrégé

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A01N 1/00 - Conservation de corps humains ou animaux, ou de parties de ceux-ci